Skip to main content
Clinical Trials/NCT01992848
NCT01992848CompletedNot Applicable

A Case-control Study of MicroRNAs a Potential Biomarkers for Coronary Artery Calcification (CAC) - An Additional Substudy to Determine the Relationship Between CAC and Bone Mineral Density and Markers of Bone Metabolism

University of Surrey4 sites in 1 country45 target enrollmentStarted: November 2013Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
45
Locations
4
Primary Endpoint
A miRNA signature in the presence and absence of coronary artery calcification (CAC)

Study Overview

Brief Summary

Coronary artery disease (CAD) remains the leading cause of mortality in the UK with an estimated 80,000 fatalities in 2010. Coronary artery calcification (CAC) is associated with atherosclerotic plaque burden and cardiovascular mortality. Mechanisms underlying isolated CAC have not been as yet been fully explained. MicroRNAs (miRNAs), known to act as regulators of gene expression, have also emerged as powerful biomarkers in the diagnosis and prognosis of cardiovascular disorders and may be used in the detection of CAC. We aim to investigate the potential for a "microRNA-signature" in patients with CAC by performing a prospective, case-controlled study to identify pathways associated with CAC in humans. Previous research has demonstrated an inverse relationship between CAC and bone mineral density (BMD), suggesting that these processes may be linked. In a further substudy we plan to define the relationship between CAC and BMD as well as a number of markers of bone metabolism.

Detailed Description

Patients will be prospectively enrolled whilst attending for elective coronary CT (computed tomography) angiography including a coronary calcium score, at the Royal Surrey County Hospital. Data regarding demographic and clinical characteristics of patients will be collected. Peripheral venous blood sampling will take place on this occasion. Coronary artery calcification scores will be estimated by a Radiologist using default software. Patients eligible for the bone metabolism substudy will be required to attend the University of Surrey for peripheral Quantitative Computed Tomography (pQCT) of bone mineral composition of the radius. In the intervening period we will ask them to complete a 4-day food diary and wear a UV dosimeter, the latter to assess typical UV exposure, for one week.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
Single (Investigator)

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age ≥ 18 years
  • Patient is able to provide written, informed consent

Exclusion Criteria

  • Age > 65 years
  • Diabetes mellitus
  • Glomerular filtration rate ≤ 60 ml/min
  • Abnormal serum calcium
  • History or clinical features of cardiac failure
  • Systemic inflammatory disease
  • Peripheral vascular disease
  • Previous history of percutaneous coronary intervention (PCI)
  • Previous history of coronary artery bypass grafting (CABG)
  • Previous history of reno-vascular disease
  • Active infection
  • Active malignancy
  • Additional clinical exclusion criteria for our sub-study are:
  • Regular use of sunbeds
  • A sun holiday one month prior to or plans for sun holiday within the study
  • Use of vitamin D supplements
  • Consumption of alcohol above recommended levels
  • Pregnancy or planned pregnancy
  • Use of a veil

Outcomes

Primary Outcomes

A miRNA signature in the presence and absence of coronary artery calcification (CAC)

Time Frame: 12 months

Secondary Outcomes

  • mRNA(messenger RNA) targets of identified miRNAs in the presence and absence of CAC(12 months)
  • Bone Mineral Density (BMD) in the presence and absence of CAC(12 months)
  • Markers of bone metabolism in the presence and absence of CAC to include: serum 25-hydroxy vitamin D, 1,25-dihydroxy vitamin D, serum calcium, albumin, parathyroid hormone, C-terminal telopeptide/CTX, and lipid profile.(12 months)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (4)

Loading locations...

Similar Trials

MAP-Calcification: MicroRNAs as Potential... | Clinical Trial